To the full analysis
Buyback calculator for Puma Biotechnology
Puma Biotechnology stock: key metrics
PBYIPuma Biotechnology had an operating margin of 16.3% and a return on invested capital (ROIC) of 51.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 12 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | no data | no data | no data |
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | 79.8% | −1,055.6% | −1,054.2% |
| 2018 | 86.2% | −37.7% | −45.3% |
| 2019 | 86.5% | −27.8% | −27.8% |
| 2020 | 82.5% | −13.5% | −26.7% |
| 2021 | 74.8% | 0.5% | −11.5% |
| 2022 | 75.8% | 10.4% | 0.0% |
| 2023 | 73.4% | 13.9% | 9.2% |
| 2024 | 72.1% | 13.4% | 13.1% |
| 2025 | 74.5% | 16.3% | 13.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | −100.0% | no data | −100.0% |
| 2008 | 200.0% | −1.6% | −100.0% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | −100.0% | no data | −100.0% |
| 2011 | −18.8% | −29.3% | −18.5% |
| 2012 | −57.6% | −63.6% | −49.0% |
| 2013 | −65.1% | −40.3% | −52.4% |
| 2014 | −100.0% | no data | −87.2% |
| 2015 | −100.0% | no data | −99.8% |
| 2016 | −100.0% | no data | −100.0% |
| 2017 | −100.0% | no data | −100.0% |
| 2018 | −100.0% | −50.0% | −43.8% |
| 2019 | −100.0% | −35.5% | −32.2% |
| 2020 | 200.0% | −16.7% | −24.6% |
| 2021 | 200.0% | 3.8% | −12.9% |
| 2022 | 0.0% | 27.3% | 0.0% |
| 2023 | 40.4% | 50.2% | 9.4% |
| 2024 | 32.9% | 46.1% | 14.2% |
| 2025 | 23.9% | 51.2% | 14.4% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.